H.C. Wainwright assumed coverage of Novavax (NVAX) with a Buy rating and $10 price target Novavax is a commercial stage biotechnology company focused on developing and commercializing novel vaccines against infectious diseases and other conditions, the analyst tells investors in a research note. The firm says the company’s vaccine platform elicits broad immune responses, is safe and well-tolerated, can be easily adapted to a wide range of antigens, and is positioned for the development of combination vaccines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax Gains FDA Approval for Nuvaxovid Vaccine
- Novavax Completes $225M Convertible Notes Transaction
- Novavax 2025-2026 Formula COVID-19 vaccine approved in U.S.
- FDA authorizes COVID vaccines for those at higher risk, Kennedy says
- Trump Trade: U.S. blocking development of offshore wind farms